Sign In
Buy OGN
$13.56
+0 (+0%)
At Close: Aug 04, 2026
Organon price target raised to $20 from $19 at Goldman Sachs
05:42pm, Tuesday, 17'th Dec 2024
Goldman Sachs raised the firm's price target on Organon to $20 from $19 and keeps a Neutral rating on the shares. The firm cites the company's announced FDA approval of VTAMA for the topical treatment
Final Trades: Amazon, American Express and Organon
01:40pm, Tuesday, 10'th Dec 2024
The CNBC 'Halftime Report' Investment Committee give their top stocks to watch for the second half.
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
10:00am, Monday, 09'th Dec 2024
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
10:00am, Tuesday, 26'th Nov 2024
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Friday, 15'th Nov 2024
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Organon: 7% Yield, 4x P/E, Big Upside Potential
12:42pm, Thursday, 14'th Nov 2024
Organon is a deep value stock with a high 7.2% yield, supported by a diversified portfolio in women's health, biosimilars, and established pharmaceuticals. Despite stock price volatility, OGN has show
Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade)
08:30am, Wednesday, 13'th Nov 2024
In this update, I'll focus on Organon's Q3 2024 results, earnings adjustments and segment performance, as well as the acquisition of Dermavant. Organon reported solid Q3 2024 results with 4% revenue g
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
10:00am, Monday, 04'th Nov 2024
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Organon & Co. (OGN) Q3 2024 Earnings Call Transcript
12:28pm, Thursday, 31'st Oct 2024
Organon & Co. (NYSE:OGN ) Q3 2024 Earnings Call Transcript October 31, 2024 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Juan Camilo Arjona Ferreira - Head of R&D Matt Wal
Organon (OGN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
11:30am, Thursday, 31'st Oct 2024
The headline numbers for Organon (OGN) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estim
Organon (OGN) Q3 Earnings and Revenues Beat Estimates
09:46am, Thursday, 31'st Oct 2024
Organon (OGN) came out with quarterly earnings of $0.87 per share, beating the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.87 per share a year ago.
Organon Reports Results for the Third Quarter Ended September 30, 2024
07:30am, Thursday, 31'st Oct 2024
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Reports Q3 2024 Earnings.
Ahead of Organon (OGN) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
10:21am, Monday, 28'th Oct 2024
Evaluate the expected performance of Organon (OGN) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
09:25am, Monday, 28'th Oct 2024
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon expands dermatology capabilities through completion of Dermavant acquisition, including nonbiologic, non-steroidal VTAMA Cream, 1%.
Earnings Preview: Organon (OGN) Q3 Earnings Expected to Decline
11:06am, Thursday, 24'th Oct 2024
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
